FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to ophthalmology, and can be used for the reduction or inhibition of angiogenesis in an individual, suffering from an eye disease, or a condition, associated with angiogenesis. For this purposethe antagonist TSPAN12 is introduced to the individual. Also claimed is a method of treating the disease or a condition of eyes, associated with undesirable angiogenesis.
EFFECT: group of inventions provides reduction of angiogenesis of vessels of the outer plexiform layer (OPL), connected with the layer of nerve fibres (NFL) of the optic nerve.
30 cl, 13 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INHIBITING ANGIOGENESIS BY EGFL8 ANTAGONISTS | 2009 |
|
RU2486200C2 |
| APPLICATION OF COMPLEMENT PATHWAY INHIBITORS FOR TREATMENT OF EYE DISEASES | 2006 |
|
RU2417099C2 |
| COMPOSITIONS AND METHODS OF SPHINGOSINE-1-PHOSPHATE BINDING | 2007 |
|
RU2460541C2 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
| USE OF COMPLEMENT PATHWAY INHIBITORS TO TREAT OCULAR DISEASES | 2010 |
|
RU2583927C2 |
| PREVENTING AND TREATING COMPLEMENT-CAUSED OCULAR PATHOLOGIES | 2008 |
|
RU2522976C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
| IL-6 ANTAGONISTS AND USES THEREOF | 2013 |
|
RU2670943C9 |
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
